Here's Where Things Went Wrong for Celldex Therapeutics, Inc. in 2017
For Celldex Therapeutics (NASDAQ: CLDX), 2016 was a horrible year. The biotech stock dropped 77% after experimental vaccine Rintega flopped in a late-stage clinical study. Celldex entered 2017 with investors having both hope and fear. Unfortunately, fear outweighed hope for much of the year.
Celldex stock is down more than 15% so far this year despite several nice rallies during the last 11 months. Here's where things went wrong for the biotech in 2017.
Source: Fool.com
Celldex Therapeutics Aktie
Positive Community-Reaktionen für Celldex Therapeutics mit mehreren Buy-Einschätzungen, keine Sell-Einschätzungen.
Das Community-Kursziel von 62 € für Celldex Therapeutics deutet auf eine deutliche Steigerung um mehr als 50% gegenüber dem aktuellen Kurs von 37.8 € hin.